AzTrials
AzTrials

Prenatal CareNCT07225595

Shifting Options Study

An observational study of Prenatal Care and Prenatal Diagnosis, run by The Cleveland Clinic at 2 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The goal of Shifting Options is to create strategies and resources that will facilitate informed decision-making about prenatal screening and diagnostic testing (PS\&D) for all pregnant patients. Read more about this study

Who is it for?
Ages 18 years and older, women only
Conditions the study is for
Prenatal Care, Prenatal Diagnosis
How many people
78 participants
Where
2 sitesUnited States
Study dates
1 Jan 2025to 28 Feb 2026
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • Adult, Older adult

Study population: Group 1 participants include those who are in their 1st or 2nd trimester of pregnancy or are 1-12 months post partum (Groups 1A, 1B and 1C). These participants will be seeking prenatal or postpartum care at one of the participating study sites. Group 2 participants will be practicing and seeing patients at one of the study sites outpatient locations.

Group 1 Inclusion Criteria:

  1. 18 years of age or older
  2. Ability to read and speak English
  3. Able to provide consent to participate in the study
  4. Have a viable intrauterine pregnancy (IUP) or 1-12 postpartum
  5. Offered routine aneuploidy screening and diagnostic testing
  6. Seeking care at one of the participating study sites

Group 1 Exclusion Criteria:

  1. <18 years of age or older
  2. Inability to read and speak English
  3. Not able to provide consent to participate in the study
  4. Does not have a viable intrauterine pregnancy (IUP) or is not 1-12 postpartum
  5. Was not offered routine aneuploidy screening and diagnostic testing
  6. Is not seeking care at one of the participating study sites

Group 2 Inclusion Criteria:

  1. Board eligible clinicians who provide prenatal care (includes OB/GYNs, CNMs, NPs, MFMs, GC, etc.)
  2. Provide outpatient obstetric care
  3. Practice at one of the study sites

Group 2 Exclusion Criteria:

  1. Not board eligible clinicians who provide prenatal care (includes OB/GYNs, CNMs, NPs, MFMs, GC, etc.)
  2. Does not provide outpatient obstetric care
  3. Does not practice at one of the study sites

Trial locations and contacts

2 sites in 1 country.

United States2 sites
  • MetroHealth Medical Center

    Cleveland, Ohio, 44109

  • Cleveland Clinic

    Cleveland, Ohio, 44195

Other trials in United States

About this study

Official title: Supporting Pregnant Patients as They Face a Changing Landscape of Prenatal Genetic Tests and Post-diagnosis Options (Shifting Options)

The goal of Shifting Options is to create strategies and resources that will facilitate informed decision-making about prenatal screening and diagnostic testing (PS\&D) for all pregnant patients. Shifting Options will determine how rapid changes in PS\&D and post-diagnosis options affect the nature and timing of resources and support patients need to make informed PS\&D decisions.

To achieve this goal, patient participants will be interviewed to identify their PS\&D decision-making needs. Then, clinician participants input will be added on how best to implement strategies that address those needs.

Read the detailed description

Study overview:

Prenatal genetic screening and diagnostic tests (PS\&D) contribute to optimal fetal/neonatal outcomes through the delivery of high-quality prenatal care. While PS\&Ds are an important part of prenatal care delivery, advances in PS\&D present a challenge to ensure pregnant patients have the information and resources to make informed decisions about their use. This complexity is due to significant advances in prenatal genomics that continue to introduce new PS\&D, increasing the number of conditions that can be detected before birth. It is also due to parallel changes in maternal-fetal medicine, pediatrics, and reproductive policy that rapidly change the options available if a fetal genetic condition is diagnosed. Consequently, patients face a growing challenge in making informed decisions about a moving target of testing and post-diagnosis options. As a result, a serious and urgent unmet clinical problem has emerged: There is a lack of evidence-based guidance to support an individualized informed decision-making process for patients amidst an increasingly complex set of reproductive healthcare choices. The objective of our study is to generate strategies and resources that will facilitate informed decision-making about PS\&D by diverse populations of pregnant patients. This project is a first step to identifying what strategies may be needed to best prepare patients for this increasingly complex decision-making landscape.

Methods:

The study will engage with two populations: (Group 1) the investigators will conduct in-depth interviews with patients to identify key factors that impact the decision-making and the resources needed to support that process, and (Group 2) with prenatal clinicians to obtain input on patient-reported decision-making priorities and resources to frame a set of initial considerations for strategy and tool implementation. Since this is an observational study, there will be no intervention, neither group will be randomized.

Study Population

Patient participants, Group 1:

Patient participants will be enrolled into 1 of 3 sub-categories: (Group 1A) includes patients who initiate care in the 1st or 2nd trimester of pregnancy to understand decision-making factors as a function of access to prenatal care, (Group 1B) includes pregnant patients with similar characteristics to category 1, but are scheduled their 2nd trimester anatomical ultrasound at one of the study sites, and (Group 1C) includes patients who are 1-12 months postpartum and delivered at one of the participating sites.

Clinician participants, Group 2:

Participants include primary OB providers, maternal-fetal specialists, genetic counselors and genetic specialists who provide outpatient obstetric care and practice at one of the outpatient clinics of the study sites.

Data Collection

Group 1 (qualitative interviews):

After completing an informed consent document, all Group 1 participants will complete an enrollment survey to collect demographic information. A member of the research team will then conduct individual semi-structured interviews with each participant. The interview guide was developed in collaboration with content experts in obstetrics, neonatology, pediatrics, genetics, medical decision-making and ethics. The interview guide will examine participants' informational and decision-making needs with respect to their (1) familiarity with the concepts associated with PS\&D, including test characteristics and implications of screens and diagnostic tests, notions of average-risk and increased-risk based on reproductive history or test result, (2) familiarity with current and forthcoming perinatal, neonatal, and pediatric interventions to improve outcomes of a child with a genetic condition or, for those participants who agree to discuss questions about pregnancy termination, familiarity with access to abortion services, (3) preferences regarding the decisional and informational domains needed when considering PS\&D use, (4) ways to approach making complex medical decisions, including tolerance of uncertainty and risk and how those preferences may change with gestational age and acquiring in-formation about the fetus, and (5) barriers and facilitators to support an informed decision-making process about initiating PS\&D that integrates information about post-diagnosis that align with the patients' needs and goals. Data collection activities will be guided by specific Human Subject Protections to ensure safeguards are in place for participants who elect to discuss opinions or actions related to pregnancy termination. All sessions will be audio-recorded for data analysis purposes.

Group 2 (qualitative interviews):

After completing an informed consent document, all Group 2 participants will complete an enrollment survey to collect demographic information. A member of the research team will then conduct individual semi-structured interviews with each participant. Interviews will be completed using the Implementation Roadmap developed by the ORD Quality Enhancement Research Initiative to guide seeking clinicians' input on patient-reported needs. This roadmap outlines three phases to guide implementation and dissemination of novel interventions. Although given the stage of this work, the investigators will focus on Phases 1 and 2 to identify how patient-reported decision-making needs may be integrated into clinical workflows: Phase 1-Planning, Framing, and Aligning Interested Parties, and Phase 2-Implementation Process Data Collection. The investigators will use the Implementation Planning Assessment Tool (IPA Tool) to develop and structure the interview guide. This will include open-ended questions about how to translate patient-reported needs into approaches that can be effectively integrated into prenatal care delivery. The interview guide will include questions about the proposed Phase 2 implementation plan. Specifically, how the process will be studied, measured, and assessed. The final section of interview guide will contain a set of questions to collect demographic and practice-related information. All sessions will be audio-recorded for data analysis purposes.

Data Analysis:

Audio-recordings will be transcribed verbatim and verified for accuracy. The investigators will use standard qualitative data analysis techniques based on grounded theory for analysis and interpretation of all qualitative data, including decisions regarding theoretical saturation to end data collection. Group 1 themes identified will be contextualized with information about the trimester of pregnancy, gravity/parity, and previous pregnancies. Group 2 themes will consider information about degree type, years in practice, and clinical setting. The investigators will conduct matrix analyses to compare themes and findings across these two groups to identify areas of alignment and discordance with Group 1 resources and Group 2 input on the ability to implement those resources in prenatal care delivery.

Keywords
shared decision-making, informed decision-making, prenatal screening and diagnostic testing

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07225595
Study groupRoleWhat they receive
Patient participants, Group 1 (N=60)Group 1 consists of patient participants. Patient participants will be fit into one of the following sub-categories: (Group 1A, N=20) patients who initiate care in the 1st or 2nd trimester of pregnancy, (Group 1B, N=20) pregnant patients with similar characteristics to category 1, but who have scheduled their 2nd trimester anatomical ultrasound at one of the study sites, and (Group 1C, N=20) patients who are 1-12 months postpartum and delivered at one of the participating sites.
Clinician participants, Group 2 (N=50)Participants (N=50) include primary OB providers, maternal-fetal specialists, genetic counselors and genetic specialists who provide outpatient obstetric care and practice at one of the outpatient clinics of the study sites.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Qualitative analysis completed using Grounded Theory in examining patient participant interviews to uncover emerging codes, memos, and themes that build strategies to support prenatal screening and diagnostic testing informed decision-making.

    The study outcome will include qualitative interview data about the prenatal screening and diagnostic testing decision-making process and a foundation for innovative strategies to support patients' informed decision-making with tandem changes in prenatal genomics and available post-diagnosis options. This work will allow researchers to characterize how patients conceptualize the shifting landscape of testing and post-diagnosis options about prenatal screening and diagnostic testing.

    Measured: 12 months

  2. Qualitative analysis completed using Grounded Theory in examining provider participant interviews to uncover emerging codes, memos, and themes that build strategies or tools to support prenatal screening and diagnostic testing informed decision-making.

    The study outcome will include qualitative interview data about the prenatal screening and diagnostic testing decision-making process and a foundation for innovative strategies to support patients' informed decision-making with tandem changes in prenatal genomics and available post-diagnosis options. This work will allow researchers to characterize how providers can support patients with the shifting landscape of testing and post-diagnosis options about prenatal screening and diagnostic testing and how these resources would best be implemented into prenatal care delivery within the clinical setting.

    Measured: 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Nov 2025
  2. Study start1 Jan 2025
  3. Primary completion28 Feb 2026
  4. Study completion28 Feb 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
78 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07225595
Sponsor's protocol ID
24-826
Status last verified
Jul 2026
First submitted
19 Nov 2024
Last updated
3 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Prenatal Care and Prenatal Diagnosis, run by The Cleveland Clinic at 2 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 3 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Qualitative analysis completed using Grounded Theory in examining patient participant interviews to uncover emerging codes, memos, and themes that build strategies to support prenatal screening and diagnostic testing informed decision-making. (time frame: 12 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Aug 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in